Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | BRAF |
Variant | L514V |
Impact List | missense |
Protein Effect | gain of function - predicted |
Gene Variant Descriptions | BRAF L514V lies within the protein kinase domain of the Braf protein (UniProt.org). L514V is predicted to lead to a gain of Braf function as indicated by moderate increase of Mek and Erk phosphorylation in culture, enhanced dimerization when expressed in cis with BRAF V600E, and is associated with resistance to Raf inhibitors (PMID: 29880583). |
Associated Drug Resistance | Y |
Category Variants Paths |
BRAF mutant BRAF act mut BRAF L514V |
Transcript | NM_004333.6 |
gDNA | chr7:g.140777066G>C |
cDNA | c.1540C>G |
Protein | p.L514V |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
XM_047420769.1 | chr7:g.140777066G>C | c.1540C>G | p.L514V | RefSeq | GRCh38/hg38 |
NM_001378474.1 | chr7:g.140777066G>C | c.1540C>G | p.L514V | RefSeq | GRCh38/hg38 |
NM_004333 | chr7:g.140777066G>C | c.1540C>G | p.L514V | RefSeq | GRCh38/hg38 |
NM_001354609.2 | chr7:g.140777066G>C | c.1540C>G | p.L514V | RefSeq | GRCh38/hg38 |
NM_001354609.1 | chr7:g.140777066G>C | c.1540C>G | p.L514V | RefSeq | GRCh38/hg38 |
NM_004333.5 | chr7:g.140777066G>C | c.1540C>G | p.L514V | RefSeq | GRCh38/hg38 |
XM_005250045 | chr7:g.140777066G>C | c.1540C>G | p.L514V | RefSeq | GRCh38/hg38 |
NM_001378468.1 | chr7:g.140777066G>C | c.1540C>G | p.L514V | RefSeq | GRCh38/hg38 |
NM_004333.6 | chr7:g.140777066G>C | c.1540C>G | p.L514V | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
BRAF L514V | breast cancer | resistant | Dabrafenib | Preclinical - Cell culture | Actionable | In a preclinical study, Tafinlar (dabrafenib) did not inhibit Erk and Mek signaling in breast cancer cells expressing BRAF L514V in culture (PMID: 29880583). | 29880583 |